GPCM
HOWL icon

Granite Point Capital Management’s Werewolf Therapeutics HOWL Stock Holding History

Granite Point Capital Management’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-55,000
Closed -$242K – 125
2022
Q1 		$242K Buy
55,000
+40,000
+267% +$280K 0.05% 113
2021
Q4 		$179K Buy
+15,000
New +$226K 0.03% 118

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Granite Point Capital Management's HOWL Position: Q2 2022 in Review

Granite Point Capital Management sold out of Werewolf Therapeutics (HOWL) in Q2 2022, closing a stake of 55,000 shares — an estimated $242K sold.

Granite Point Capital Management first reported a position in HOWL in Q4 2021 and held it in 2 quarters. The position peaked at $242K in Q1 2022. 46 funds tracked by Wall St. Rank hold HOWL as of Q2 2022.

  • Granite Point Capital Management reported no remaining Werewolf Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Granite Point Capital Management sold 55,000 Werewolf Therapeutics shares in Q2 2022, an estimated $242K.
  • Granite Point Capital Management first reported a position in Werewolf Therapeutics in Q4 2021 and held it in 2 quarters.
  • Granite Point Capital Management's Werewolf Therapeutics position peaked at $242K in Q1 2022.
  • 46 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2022.

Based on Granite Point Capital Management's 13F filing for Q2 2022, filed 5 Aug 2022.